These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1079276)

  • 21. Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients.
    Fossati G; Canevari S; Pierotti MA; Vezzoni P; Porta GD; Vaglini M
    J Natl Cancer Inst; 1979 Jun; 62(6):1381-5. PubMed ID: 286110
    [No Abstract]   [Full Text] [Related]  

  • 22. Recall antigen delayed-type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates.
    Morris DL; Hersh EM; Hsi BP; Gutterman JU; Marshall MM; Mavligit GM
    Cancer Res; 1979 Jan; 39(1):219-26. PubMed ID: 761192
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunologic response in patients with melanoma of the skin].
    Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
    Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of malignant melanoma with vaccinia virus.
    Roenigk HH; Deodhar S; St Jacques R; Burdick K
    Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
    [No Abstract]   [Full Text] [Related]  

  • 29. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 30. [The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].
    Wallack MK
    Nouv Presse Med; 1979 May; 8(23):1919-21. PubMed ID: 223123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
    Johnston D; Bystryn JC
    Mol Biother; 1989; 1(4):218-22. PubMed ID: 2818873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low doses of chemotherapy to inhibit suppressor T cells.
    Berd D
    Prog Clin Biol Res; 1989; 288():449-58. PubMed ID: 2566177
    [No Abstract]   [Full Text] [Related]  

  • 34. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunological studies in intraocular tumors].
    Kotelianskiĭ EO
    Oftalmol Zh; 1982; 37(1):54-8. PubMed ID: 7043350
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma.
    Bruckner HW; Mokyr MB; Mitchell MS
    Cancer Res; 1974 Jan; 34(1):181-3. PubMed ID: 4588545
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification of soluble human melanoma-associated antigens.
    Roth JA; Slocum HK; Pellegrino MA; Holmes EC; Reisfeld RA
    Cancer Res; 1976 Jul; 36(7 PT 1):2360-4. PubMed ID: 776393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
    Berd D; Wilson EJ; Bellet RE; Mastrangelo MJ
    Cancer Res; 1979 Nov; 39(11):4472-6. PubMed ID: 387215
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dermal reactions to melanoma autohomogenates].
    Tritsch H
    Hautarzt; 1970 Jun; 21(6):258-65. PubMed ID: 5520644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.